Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. trades under the ticker KPTI. The share price is $0.02, up 0.00% on the day, which values the company at $394.66K. Price as of 17 Nov 2026, 18:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $0.02+0.00% today
- Market value
- $394.66K
- Funk Score
- 14/100
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Karyopharm Therapeutics Inc. in more detail
KPTI trades at -0.0× next year's expected earnings, 0.0× sales.
Over the last five fiscal years Karyopharm Therapeutics Inc. has compounded revenue 6.2% a year. Its Funk Score is 14 out of 100 (financial strength 1.4, profitability 0.0, growth 2.8, each out of 10).
In its favour: Operating margin is expanding. Worth checking: Altman Z in the distress zone; Weak Piotroski score.
1 of the superinvestors tracked here hold KPTI, including Peter Kolchinsky (0.2% of the portfolio).
Superinvestors holding KPTI
1 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management0.16% of portfolio · $18.7M · Q2 2026
Karyopharm Therapeutics Inc. (KPTI): questions and answers
What is Karyopharm Therapeutics Inc.'s market cap?
Karyopharm Therapeutics Inc. is valued at $394.66K at a share price of $0.02.
How fast is Karyopharm Therapeutics Inc. growing?
Over the last five fiscal years Karyopharm Therapeutics Inc.'s revenue grew 6.2% a year; over ten years revenue grew 89.1% a year.
Does KPTI pay a dividend?
Karyopharm Therapeutics Inc. does not currently pay a regular dividend.
Which famous investors own KPTI?
In their latest quarterly filings, Peter Kolchinsky (0.2% of the portfolio) hold KPTI. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
When does Karyopharm Therapeutics Inc. report earnings next?
Karyopharm Therapeutics Inc.'s next earnings report is expected on November 20, 2026. The date comes from the market data feed and companies do move it.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Karyopharm Therapeutics Inc. (KPTI) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/KPTI
Underlying data: Yahoo Finance; company filings with the SEC.